Skip to content

Sex, hormones, pregnancy and lactation

TL;DR — Migraine becomes two- to threefold more prevalent in females after puberty, and falling estrogen after sustained exposure is the leading mechanism for menstrual attacks (Nappi 2022, PMID 35456034). Menstrual migraine affects about 20–25% of women with migraine in population estimates, is usually without aura and produces longer, more disabling, recurrence-prone attacks; prospective diaries are needed because chance clustering and recall misclassify it (Vetvik 2021, PMID 33600767; Verhagen 2022, PMID 35514214). Short-term perimenstrual prevention with frovatriptan or naratriptan has randomized evidence, but the strategy adds triptan days and can create overuse when non-menstrual attacks are also frequent (Silberstein 2004, PMID 15277618; Mannix 2007, PMID 17635595). Migraine without aura often improves during pregnancy and recurs postpartum, while new or changed pregnancy/postpartum headache demands secondary-cause assessment (Sances 2003, PMID 12662187; Negro 2017, PMID 29052046). Pregnancy and lactation decisions require drug-specific human data; absence of a malformation signal for triptans is not proof of no fetal/neonatal effect, and evidence for gepants/CGRP antibodies remains sparse (Marchenko 2015, PMID 25644494).

Sex is an epidemiological observation, not one mechanism

Level Candidate contributor Evidence boundary
Developmental Puberty-associated hormonal and neural change Correlated changes cannot isolate cause
Activational Cyclic estrogen/progesterone fluctuation Strong temporal signal in menstrual migraine
Genetic Sex-shared and sex-influenced polygenic effects Does not explain all prevalence difference
CGRP/trigeminal Hormone modulation of CGRP signaling Mostly experimental; clinical selector absent
Social/clinical Exposure, roles, recognition and care-seeking Varies across settings and generations

Women also report greater disability and longer disease exposure during reproductive years. “Female hormones cause migraine” is too broad: many attacks are non-menstrual, pregnancy responses differ, and men also have migraine (Burch 2020, PMID 31579938).

Menstrual migraine definitions

The ICHD appendix defines the perimenstrual window as day −2 through +3, with day 1 the first day of bleeding, in at least two of three cycles. Pure menstrual migraine occurs only in that window; menstrually related migraine also occurs at other times.

Phenotype Required pattern Why diary matters
Pure menstrual migraine Attacks only day −2 to +3 in ≥2/3 cycles Rare and easily overcalled retrospectively
Menstrually related migraine Window-linked attacks plus other attacks High background frequency creates chance overlap
Self-reported “hormonal migraine” No formal requirement Poor concordance with prospective criteria

In a 607-woman e-diary study, self-report agreed poorly with diary criteria; pure menstrual migraine was <1%, and statistical-versus-diary concordance was κ=0.28 (Verhagen 2022, PMID 35514214). Population synthesis estimates menstrual migraine in 20–25% of female migraineurs, with much higher clinic estimates (Vetvik 2021, PMID 33600767).

Menstrual attack phenotype

Perimenstrual attacks are generally without aura, last longer, recur more and respond less consistently than non-menstrual attacks in the same women (MacGregor 2014, PMID 25100506; Nierenburg 2015, PMID 26264117). Estrogen withdrawal after several days of higher exposure is the central model; prostaglandins and trigeminovascular/CGRP interactions may modulate the attack (Ashkenazi 2007, PMID 17685879; Nappi 2022, PMID 35456034).

Clinical pattern Treatment implication
Predictable cycle and low non-menstrual frequency Short-term prevention may minimize continuous exposure
Unpredictable cycles Calendar-triggered prophylaxis risks mistiming/excess use
Frequent non-menstrual attacks Continuous prevention may be more coherent
Long recurrence-prone attacks Sustained endpoint/longer-acting strategy matters
Aura with estrogen exposure Vascular/contraceptive assessment differs from migraine without aura

Acute and perimenstrual strategies

Acute treatment follows general migraine evidence: NSAID, triptan, gepant or combination selected by severity, route and contraindication. Menstrual attacks’ duration makes sustained pain freedom especially important (Maasumi 2017, PMID 27910087).

Short-term prevention usually begins before expected menses and continues 5–6 days. It is not a universal monthly prescription; predictable timing and total acute/preventive treatment days determine suitability.

Strategy Evidence Constraint
Frovatriptan twice daily Three-period randomized crossover and evidence review support acute/short-term prophylactic use (Silberstein 2004, PMID 15277618; MacGregor 2014, PMID 24904224) Triptan exposure; prediction; class contraindications
Naratriptan 1 mg twice daily Pilot and two larger randomized studies support short-term prevention (Newman 2001, PMID 11264684; Mannix 2007, PMID 17635595) Some dose/regimen inconsistency; overuse days
Naproxen/other NSAID Used around menses with smaller evidence base GI/renal risk and pregnancy timing
Magnesium Limited heterogeneous evidence; gynecologic review evidence is not equivalent to migraine-specific triptan RCTs (Fiorentini 2017, PMID 28392498) Formulation/dose and GI effects
Estrogen supplementation Can blunt withdrawal in selected regimens Delayed withdrawal headache and vascular/reproductive context

Frovatriptan’s ~26-hour half-life supports sustained coverage, but pharmacokinetic elegance is not proof of superiority over other strategies (Markus 2007, PMID 18001261). Systematic review found multiple acute and preventive options but heterogeneous endpoints and relatively few high-quality trials (Nierenburg 2015, PMID 26264117).

Hormonal contraception and hormone therapy

Combined hormonal contraception can improve, worsen or leave migraine unchanged; hormone-free intervals can trigger withdrawal attacks. Migraine with aura is associated with ischemic stroke, and estrogen-containing contraception plus smoking or vascular factors can increase absolute risk. Migraine phenotype, estrogen dose, age and other vascular exposures must be separated (Todd 2018, PMID 29855724).

Question Required distinction
Is there aura? Visual/sensory focal aura, not nonspecific blur/dizziness
Did aura begin/change after hormones? Temporal relationship may change risk discussion
Estrogen or progestin-only? Vascular and withdrawal profiles differ
Continuous or cyclic? Hormone-free interval drives some attacks
Smoking/hypertension/thrombosis? Absolute stroke risk is multiplicative, not migraine-only

Observational vascular evidence cannot tell whether stopping estrogen reduces migraine or stroke risk by a specific amount for an individual. Contraceptive choice is a joint reproductive and vascular decision, not a headache-only intervention.

Course during pregnancy

Prospective diary studies show migraine—especially without aura—often improves as pregnancy progresses, likely reflecting sustained hormone levels. In 49 women followed prospectively, improvement increased across trimesters and headache recurred postpartum (Sances 2003, PMID 12662187). The larger MIGRA study enrolled 2,126 pregnant women, with detailed diaries in 208 meeting migraine criteria, and confirmed pregnancy/puerperium change with individual variation (Kvisvik 2011, PMID 21442333).

Aura can first appear or change during pregnancy. In a prospective cohort of 1,631 women, headache and transient focal neurological symptoms required careful classification; pregnancy does not make focal symptoms automatically migrainous (Ertresvåg 2005, PMID 15740574).

Period Typical population pattern Safety implication
First trimester Nausea/vomiting and medication exposure concerns; variable migraine Organogenesis and dehydration matter
Second/third trimester Many without-aura patients improve New headache raises preeclampsia/vascular differential
Immediate postpartum Recurrence common; sleep/hormone shift Preeclampsia, venous thrombosis, hemorrhage and dural-puncture headache
Lactation Individual course; drug transfer varies Milk exposure and infant maturity are drug-specific

Pregnancy red flags

Pregnancy/postpartum secondary causes include hypertensive disorders, cerebral venous thrombosis, arterial dissection, stroke/hemorrhage, pituitary apoplexy, infection and post-dural-puncture headache. Systematic review emphasizes that primary headache is common but dangerous secondary headache must be excluded when pattern or examination changes (Negro 2017, PMID 29052046).

A prospective postpartum cohort found headache common in the first month and classified primary versus symptomatic causes; timing and phenotype alone were insufficient for every case (Anzola 2017, PMID 29073663).

Medication evidence in pregnancy

Randomized pregnancy trials are scarce for ethical/practical reasons, so evidence comes from registries, claims cohorts and meta-analysis. These designs are vulnerable to confounding by migraine severity, indication, live-birth bias and incomplete over-the-counter exposure.

Evidence Finding Boundary
Norwegian cohort, 69,929 pregnancies No overall major-malformation association with first-trimester triptan exposure; later exposure associated with some delivery outcomes Observational and drug mix (Nezvalová-Henriksen 2010, PMID 20132339)
1991–2013 triptan meta-analysis No significant major congenital-malformation/prematurity signal versus migraine controls; spontaneous-abortion comparisons depended on control group Residual confounding and limited non-sumatriptan data (Marchenko 2015, PMID 25644494)
Claims vs pregnancy registry Demonstrated complementary ascertainment and limitations for triptan safety Live births and coding constrain outcomes (Yusuf 2018, PMID 30240072)
Quebec cohort Examined triptans and DHE for prematurity, low birth weight, malformations and spontaneous abortion Confounding and small DHE exposure (Bérard 2021, PMID 34588467)

Ergot derivatives are avoided because of vasoconstrictive/uterotonic concerns; an older DHE cohort could not establish reassurance (Bérard 2012, PMID 22612391). Valproate and topiramate have major reproductive hazards and should not be treated as routine pregnancy preventives.

Evidence for CGRP antibodies and gepants remains substantially smaller than for sumatriptan. Long antibody half-life means exposure persists after discontinuation. Mechanistic concern about CGRP in uteroplacental physiology plus sparse human denominators justifies caution without claiming demonstrated teratogenicity.

The 2026 EHF sex-specific consensus offers agent-level pregnancy and lactation recommendations, but only 37 studies informed 10 evidence summaries across 24 questions and Delphi consensus filled many gaps. Its safety statements should therefore be distinguished from adequately powered comparative pregnancy-outcome evidence (Braca 2026, PMID 41998499).

Lactation

Lactation safety depends on milk transfer, oral bioavailability to the infant, infant age/prematurity, dose timing and maternal need. Large proteins may have low milk transfer and poor infant oral absorption, but direct data for CGRP antibodies are sparse; “large molecule” is not a substitute for measured outcomes (Burch 2020, PMID 31579938).

Sumatriptan has the longest clinical experience among triptans; NSAIDs differ in half-life and infant exposure. Drug-specific lactation resources and current labels should be checked rather than applying class-wide pregnancy rules.

Open questions

  • Can menstrual-migraine criteria incorporate chance clustering at high attack frequency? (Verhagen 2022, PMID 35514214)
  • Which short-term preventive minimizes total treatment days and recurrence in head-to-head trials? (Nierenburg 2015, PMID 26264117)
  • What are fetal, placental and infant outcomes after CGRP antibody/gepant exposure in adequately powered prospective registries? (Burch 2020, PMID 31579938)
  • Does successful menstrual suppression change aura or vascular risk independently of contraceptive formulation? (Todd 2018, PMID 29855724)
  • Which postpartum headache prediction rule safely separates recurrence from secondary vascular disease? (Negro 2017, PMID 29052046; Anzola 2017, PMID 29073663)

References

  1. Burch R. Menstrual migraine and migraine during pregnancy and lactation. Headache. 2020. PMID 31579938
  2. Nappi RE, et al. Role of estrogens in menstrual migraine. Cells. 2022. PMID 35456034
  3. Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing recognition. Lancet Neurol. 2021. PMID 33600767
  4. Verhagen IE, et al. Validation of ICHD-3 criteria for menstrual migraine. Cephalalgia. 2022. PMID 35514214
  5. Maasumi K, et al. Menstrual migraine and treatment options. Headache. 2017. PMID 27910087
  6. Nierenburg H, et al. Preventive and acute treatment of menstrual migraine: systematic review. Headache. 2015. PMID 26264117
  7. Ashkenazi A, et al. Menstrual migraine: hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2007. PMID 17685879
  8. Silberstein SD, et al. Frovatriptan for intermittent prevention of menstrual migraine. Neurology. 2004. PMID 15277618
  9. Newman L, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine. Headache. 2001. PMID 11264684
  10. Mannix LK, et al. Naratriptan for short-term prevention of menstrually related migraine. Headache. 2007. PMID 17635595
  11. Markus F, et al. Frovatriptan review. Expert Opin Pharmacother. 2007. PMID 18001261
  12. MacGregor EA. Frovatriptan for treatment of menstrual migraine. Int J Womens Health. 2014. PMID 24904224
  13. Silberstein SD, et al. Menstrual migraine: hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2014. PMID 25100506
  14. Todd C, Lagman-Bartolome AM. Women and migraine: role of hormones. Curr Neurol Neurosci Rep. 2018. PMID 29855724
  15. Sances G, et al. Course of migraine during pregnancy and postpartum: prospective study. Cephalalgia. 2003. PMID 12662187
  16. Kvisvik EV, et al. Headache and migraine during pregnancy and puerperium: MIGRA study. J Headache Pain. 2011. PMID 21442333
  17. Ertresvåg JM, et al. Headache and transient focal neurological symptoms during pregnancy. Acta Neurol Scand. 2005. PMID 15740574
  18. Negro A, et al. Headache and pregnancy: systematic review. J Headache Pain. 2017. PMID 29052046
  19. Anzola GP, et al. Postpartum headache: prospective study. J Oral Facial Pain Headache. 2017. PMID 29073663
  20. Nezvalová-Henriksen K, et al. Triptan exposure during pregnancy: Norwegian cohort. Headache. 2010. PMID 20132339
  21. Marchenko A, et al. Pregnancy outcome after prenatal triptan exposure: meta-analysis. Headache. 2015. PMID 25644494
  22. Yusuf A, et al. Electronic databases for pregnancy safety: triptan case study. Pharmacoepidemiol Drug Saf. 2018. PMID 30240072
  23. Bérard A, et al. DHE and triptan use during pregnancy and adverse outcomes. Sci Rep. 2021. PMID 34588467
  24. Bérard A, et al. DHE use during gestation and adverse pregnancy outcomes. Headache. 2012. PMID 22612391
  25. Parazzini F, et al. Magnesium in gynecological practice: literature review. Magnes Res. 2017. PMID 28392498
  26. Braca S, et al. Sex-specific management of migraine: EHF systematic review and consensus statement. J Headache Pain. 2026. PMID 41998499